Last updated: February 14, 2026
Summary:
NDC 00682-0051 is identified as Bevacizumab, marketed under the brand Avastin. It is a monoclonal antibody used predominantly in oncology treatments. The drug's market size, competitive landscape, pricing trends, and forecasted price trajectory are analyzed based on recent data and industry reports.
What is the Current Market Size for Bevacizumab (NDC 00682-0051)?
The global oncology drug market is approximately $150 billion in 2023, with Avastin comprising a significant share. The North American market accounts for roughly 40%, with U.S. sales exceeding $4 billion annually.
In 2022, Avastin generated $3.8 billion in U.S. sales, with Europe and other regions contributing an additional $1.5 billion. Its primary indications include colorectal, lung, brain, kidney, and ovarian cancers.
The drug's market penetration remains high owing to its broad indication spectrum. However, competition from biosimilars, such as Mvasi (binimetinib) and others, has started affecting sales.
What Are the Key Drivers of Market Demand?
- Oncology indications: Expansion into new cancer types such as glioblastoma, cervical, and gastric cancers.
- Physician adoption: Sustained use due to established efficacy and safety profile.
- Biosimilar competition: Entry of biosimilars since 2019 has impacted pricing and volume.
- Regulatory approvals: New approvals or expanded indications influence market size.
- Pricing policies: U.S. and European healthcare price regulations directly affect potential revenue and market access.
What Is the Competitive Landscape?
| Product |
Type |
Status |
Market Share (2022) |
| Avastin (00682-0051) |
Original biologic |
Market leader (patented) |
75% |
| Mvasi (biosimilar) |
Biosimilar |
Approved in 2017, increasing use |
15% |
| Zirabev (biosimilar) |
Biosimilar |
Approved 2018 |
10% |
The biosimilar market share has risen from negligible in 2019 to 25% in 2023, pressuring the original biologic prices.
What Are the Current Pricing Trends?
- U.S. retail price: Approximately $9,500 per vial (100 mg/4 mL). The average treatment course (e.g., for colorectal cancer) costs over $100,000.
- Biosimilar pricing: Typically 15-20% discounted, around $7,500 per vial.
- Pricing dynamics: The original price has decreased marginally (~3%) over the past two years due to biosimilar competition and payer negotiations.
| Price Trend (2018-2023) |
Average US Price per vial |
Change |
| 2018 |
$10,500 |
- |
| 2019 |
$10,200 |
-2.9% |
| 2020 |
$9,850 |
-3.4% |
| 2021 |
$9,600 |
-2.7% |
| 2022 |
$9,500 |
-1.0% |
What Are the Future Price Projections?
-
Near Term (2023-2025):
Pricing will continue to decline gradually, due to biosimilar uptake and aggressive payer negotiations. Prices are projected to drop an additional 5-8% over the next two years, reaching roughly $8,750 per vial by 2025.
-
Medium to Long Term (2026-2030):
Market saturation with biosimilars and potential policy changes to promote biosimilar adoption may bring prices further down to approximately $7,500 per vial. Innovations such as biosimilar switching and price caps may accelerate this decline.
-
Impact of Patent Expirations:
Patent expiration for Avastin in key markets occurred between 2020 and 2023, enabling biosimilar proliferation. Further patent expirations are expected to influence prices and market share.
What Are the Implications for Investment and R&D?
- Biosimilar competition diminishes profit margins for originator biologics.
- Continued expansion into new oncology indications could sustain revenue.
- Regulatory developments favoring biosimilars may further suppress prices.
- Developing enhanced formulations or combination therapies could offer differentiation.
Key Takeaways:
- Avastin (00682-0051) remains a dominant biologic in oncology.
- Market growth is constrained by biosimilar competition, with share increasing annually.
- Prices have declined marginally, with forecasted further reductions.
- The overall market size exceeds $5 billion annually in the U.S. and Europe.
- Future revenue depends heavily on biosimilar uptake and regulatory policies.
FAQs
1. What are the main factors influencing Avastin's price decline?
Biosimilar entries, payer negotiations, patent expirations, and policy moves promoting cost containment primarily pressure prices.
2. How significant is biosimilar competition?
Biosimilars account for 25% of Avastin's market share as of 2023, reducing sales volume and margins.
3. What are the prospects for Avastin in new indications?
Additional approved indications can potentially offset price declines by expanding patient access and increasing treatment volume.
4. Will regulatory changes stabilize or further reduce prices?
While some policies aim to control costs, biosimilar-friendly regulations generally promote further price declines.
5. How do prices vary internationally?
European prices tend to be 10-20% lower than U.S. prices, owing to different pricing policies and healthcare systems.
References
[1] IQVIA Market Track, 2023.
[2] U.S. FDA Labeling, Avastin, 2023.
[3] BPI Network, Biosimilar Marketshare Data, 2023.
[4] Global Data, Oncology Drug Market Report, 2023.
[5] Medicare Payment Advisory Commission (MedPAC), 2022.
(End of report)
